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Background: Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite
proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought to study,
across three physician specialties, a range of factors that have been argued to have a disproportionate effect on
treatment decisions.
Methods: Cross-sectional survey of Canadian Family Doctors (FD: n = 500), Geriatricians (G: n = 149), and Internal
Medicine specialists (IMS: n = 500). Of these, 1032 physicians were contactable, and 335 completed and usable
responses were received. Survey questions and clinical vignettes asked about the frequency with which they see
patients with atrial fibrillation, treatment practices, and barriers to the prescription of anticoagulants.
Results: Stated prescribing practices did not significantly differ between physician groups. Falls risk, bleeding risk
and poor patient adherence were all highly cited barriers to prescribing warfarin. Fewer geriatricians indicated that
history of patient falls would be a reason for not treating with warfarin (G: 47%; FD: 71%; IMS: 72%), and
significantly fewer changed reported practice in the presence of falls risk (χ2 (6) = 45.446, p < 0.01). Experience of a
patient having a stroke whilst not on warfarin had a significant impact on vignette decisions; physicians who had
had patients who experienced a stroke were more likely to prescribe warfarin (χ2 (3) =10.7, p = 0.013).
Conclusions: Barriers to treatment of atrial fibrillation with warfarin affect physician specialties to different extents.
Prior experience of a patient suffering a stroke when not prescribed warfarin is positively associated with intention
to prescribe warfarin, even in the presence of falls risk.Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia,
affecting 5% of the population over the age of 65 [1,2] and
around 1% in individuals >20 years of age [3]. AF is a lead-
ing cause of ischemic stroke, [4] increasing the risk of
stroke six-fold [5] and is estimated to account for approxi-
mately 15% of all strokes [6,7]. Consequently, manage-
ment of AF involves preventing AF-related complications
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unless otherwise stated.Management of AF often relies on the administration of
antithrombotic therapy. Until very recently, such therapy
has chiefly taken the form of antiplatelet drugs, such as as-
pirin, or anticoagulants including vitamin k agonists such
as warfarin. The prescription of warfarin has been shown
to significantly reduce the risk of ischemic stroke [8,9].
However, the use of warfarin requires close monitoring
[10] which has been and will remain an impediment to
warfarin use [11,12]. Furthermore, warfarin is itself associ-
ated with a small risk of major bleeding [13]. Studies have
suggested that warfarin continues to be taken by only 30–
60% of appropriate patients [5,14]. A recent systematic re-
view indicated no clear pattern of improved prescribing
practice in 29 studies over a 10 year period [14]. While
new oral anticoagulants (OACs), such as dabigatran, rivar-
oxaban, and apixaban have been developed, [4,15-18] andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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warfarin is likely to remain an important mode of preven-
tion of strokes in patients with AF, at least in the short- to
medium-term. In part this will likely be due to the cost of
the new drugs, and uncertainties around their risks in cer-
tain sub-populations such as those with poor renal func-
tion or intolerance of these new anticoagulants [18]. At
the same time, attempts to improve prescribing practice
through the use of genotyping prior to prescription have
produced mixed results, with limited clinical utility [20].
Given these current uncertainties, improving prescribing
practices for warfarin will remain an important element of
clinical practice.
To date, a number of barriers to warfarin prescription
have been identified. In particular, attention has been
drawn to the impact of the perceived risk of the patient
falling, with a concomitant risk of bleeds [2,21-23].
While some authors have suggested that the perceived
risk associated with falls may be overestimated, and that
it would require a substantial number of falls for the
risks of falls to outweigh the benefits of warfarin pre-
scription, [2,21] others have noted that trials of warfarin
for the prevention of stroke in patients with atrial fibril-
lation have been highly selective in their recruitment,
often excluding patients at high risk of falls or at high
risk of stroke [24]. As such, it may be that physicians are
forced to extrapolate from trial data that does not match
the patient in front of them or rely on personal experi-
ence when making decisions in practice. While the risk
of falls has been implicated in decisions not to prescribe
warfarin, there has, to date, been little research attempt-
ing to assess the impact that the perceived risk of patient
falls has on the decision-making of physicians when
considering the prescription of warfarin for patients with
atrial fibrillation.
Other work suggests prior experience with serious ad-
verse events may also affect prescribing practice [22,25].
This has been argued to stem from the “availability heur-
istic”, [26] a general psychological mechanism under-
lying many human judgements where the judgment of a
particular outcome probability can be based on the ease
with which one can recall instances of similar outcomes
[27]. Because vivid events are more easily recalled than
mundane ones, memory of a single catastrophic bleed
event while on warfarin might lead to a generalized
overestimation of the probability of bleeding for subse-
quent patients, and consequently reduced warfarin use.
Indeed, a recent meta-analysis concluded that there is
a need to consider provider characteristics such as previ-
ous adverse events in patients on warfarin, and the
extent to which these effects influence prescribing deci-
sions across physician groups [28].
The aim of this study was to explore these factors that




This survey formed part of a larger project that sought to
identify factors that influence physicians' decisions around
the use of anti-coagulant treatment for atrial fibrillation,
and focused on the use of antithrombotic treatment of
AF. Physician contact details were obtained from the 2005
Canadian Medical Association Directory. The survey was
administered to three samples of Canadian physicians:
Family Doctors, Internal Medicine Specialists, and
Geriatricians. Internal Medicine Specialists were se-
lected as a broad physician grouping that included sub-
specialties of interest, such as cardiology, but which
could not be selected individually with sufficient confi-
dence, due to variation in the way physicians were cate-
gorized. Physicians were included if they were listed as
having an “active” practice status, and a specialty code
of family or internal medicine. In both cases, a random
sample of 500 individuals was selected. In addition to
these groups, all physicians whose primary specialty was
listed as geriatrics were included (n = 149).
Design and administration was optimized using the
Dillman Tailored Design Method, a tested and widely used
approach to survey research [29,30]. In line with this
approach, physicians received an initial pre-notification
letter. The survey was then mailed one week later together
with a covering letter that described the purpose of the
study, indicated source of funding, and reported ethical
approval from the Ottawa Hospitals Research Ethics Board.
Return of the survey was taken as tacit consent. Three
reminders and two replacement surveys were mailed to
non-responders at two-week intervals. Correspondence was
addressed to the individual physicians, and signed by the
principal investigator (JCB). In addition, a financial incen-
tive ($20) was provided for completion of the survey.
Surveys were completed between June and August 2007.
Survey instrument
The survey was developed and based on a narrative re-
view of the literature in order to gather evidence regard-
ing physicians’ self-reported practice, reasoning around
warfarin use in practice and attitudes towards previously
identified barriers to the prescription of warfarin. Physi-
cians were asked about their engagement with patients
with AF, their prescribing practices when seeing a new
patient with AF, the situations under which they would
not prescribe warfarin, and other potential barriers to
the prescription of warfarin. Potential barriers were
drawn from a number of sources including the recom-
mendations of physician organizations, CHADS2, [31]
and the scientific literature; [7,32-34] we looked both for
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lated to treatment with warfarin, or those that were un-
related to outcomes, but which may be thought to be
related by some physicians.
Initial instructions indicated that unless otherwise spe-
cified, all questions in the survey dealt with patients
whose primary reason for seeking medical attention is
AF and where AF was defined as established paroxysmal
or chronic AF, involving chronic or recurrent episodes
over a period of more than 48 hours. Respondents were
asked to mark a line on a graded scale ranging from 0-
100% to indicate the percentage of their new patients for
which they would prescribe different anti-thrombotic
therapies. To indicate the items deemed relevant to war-
farin use, physicians were asked two questions. The first
asked respondents “When you do NOT initiate warfarin
(Coumadin) treatment for patients who have chronic
atrial fibrillation, what reasons account for this deci-
sion?” Six options: patient judged to be of low risk of
thromboembolic event (e.g., stroke); bleeding risk (e.g.,
liver disease); fall risk (e.g., alcohol abuse or frail older);
advanced age; expected poor patient compliance in
monitoring INR; and monitoring/ management logistical
issues, were provided together with an open ended
‘other’ option.
To explore the role of perceived risk of bleeding on
stated prescribing, three vignettes were created (Table 1).
Vignettes reflected cases of low stroke and low falls risk,
high stroke and low falls risk, and high stroke and high
falls risk, with risk of stroke determined according to the
CHADS2 scale [31]. To examine the potential effect of
the availability heuristic on decisions of whether to pre-
scribe warfarin, respondents were also asked about their
experience of adverse events due to the prescription or
non-prescription of warfarin. The questionnaire is pro-
vided in Additional file 1.
Data analysis
Data was entered into and analyzed using IBM SPSS Sta-
tistics v19 (SPSS Inc., 2010). A 10% data entry check was
conducted by two researchers and indicated a 97.6%
concordance, with discrepancies resolved through dis-
cussion and reassessment of the returned survey. De-
scriptive statistics were used to summarize the data from
the total sample and the assessment of differences be-
tween physician groups. Comparisons between groups
were made using χ2 and Kruskal-Wallis tests as appro-
priate; with column proportions compared using a z test.
A level of p < 0.05 was accepted as significant.
Results
Of the 1149 participants identified 117 were excluded
based on the survey being ‘returned to sender’, the phys-
ician no longer being at that address, or because theydid not see patients with Atrial Fibrillation. Consequently,
1032 questionnaires were included in the study (Table 2).
The majority of physicians (88%) were under the age of 50
with almost two thirds (66%) of respondents being male.
Assessment of non-responders was limited to the infor-
mation available in the CMA Directory (i.e. sex, location
and specialty). Responders did not differ significantly to
non-responders on any of these variables.
A total of 335 surveys were returned in which physi-
cians reported seeing at least one patient with atrial fib-
rillation per year (response rate 32.5%). Of these, 154
(46%) were family doctors, 129 (38.5%) internal medicine
specialists, and 52 (15.5%) were geriatricians.
Standard AF treatment practice
Table 3 presents physician responses regarding the per-
centage of patients with atrial fibrillation to whom they
report administering anti-thrombotic therapies. Warfarin
was the most common treatment with a mean of 73% of
physicians indicating this would be the drug they admin-
istered to new patients. There was no statistically signifi-
cant variation between physician types in terms of the
reported rates of warfarin use (p =0.28), no antithrom-
botic therapy (p = 0.21), aspirin (p = 0.24), Plavix (Clopi-
dogrel) (p = 0.11), or other treatments (p = 0.46).
Reasons for non-prescription of warfarin
Table 4 shows the reasons reported for not prescribing
warfarin, stratified by physician group. There were statis-
tically significant differences between physician groups
for all factors with the exception of the ‘other’ category.
Generally, geriatricians differed in their responses to the
other two disciplines. A significantly lower proportion of
geriatricians indicated that risk of falls would be a reason
not to prescribe warfarin, (geriatricians (G):47%; family
doctors (FD): 71%; and internal medicine specialists
(IMS): 72%). This was also the case for advanced age (G:
7.8%; FD: 31.1%; IMS: 25.8%). Geriatricians also indi-
cated high levels of concern regarding expected poor
patient adherence (G: 74.5%; FD: 49%; IMS: 66.4%),
although this did not significantly differ from internal
medicine specialists.
Falls risk, bleeding risk and poor patient adherence
were all highly cited reasons for not treating with war-
farin. A significantly higher proportion of internal medi-
cine specialists indicated that bleeding risk would be a
barrier to the prescription of warfarin. Attitudes to mon-
itoring and management issues differed across all three
physician types with 53% of geriatricians indicating mon-
itoring or management issues as reasons for non-
prescription compared with only 15% of family doctors
and 30% of internal medicine specialists.
Table 5 describes the reported experience of adverse
events among the three physician groups. Overall, bleeds
Table 1 Details of the case vignettes
Vignette Description:
1 Low Stroke risk, Low risk of falls
History: The patient is a 53 year old male, a teacher who
participates in regular physical activity. He has a 5-year
history of chronic atrial fibrillation which is asymptomatic.
For rate control, he takes metoprolol 25 mg bid. He is not
taking any antithrombotic therapy. The rest of his medical
history is unremarkable, including no history of diabetes,
hypertension, or other cardiovascular risk factors. He is
taking no other regular medications.
Physical exam: He appears fit. Blood pressure is 130/65;
pulse is 78 and irregularly irregular. Cardiac exam is normal
except for the irregular rhythm; and the rest of the physical
exam is also normal. All laboratory work including complete
blood count, electrolytes, urea, creatinine and TSH are
normal. ECG confirms atrial fibrillation at 80 beats per
minute, but is otherwise unremarkable. Echocardiogram
(performed the next day) also shows atrial fibrillation, but
is otherwise unremarkable (normal chamber sizes, normal
systolic function, and no valvular abnormalities).
2 High Stroke Risk, Low risk of falls
History: The patient is a 74 year old woman. She lives at
home with her husband; she is cognitively intact (as is her
husband) and is fully independent and active for her age.
Past medical history includes hypertension and an ischemic
stroke 4 years ago, with no residual deficits. Current
medications include hydrochlorothiazide 25 mg daily and
atenolol 50 mg daily. She recalled taking aspirin in the
past, but stopped on her own years ago. She prefers to
walk with a cane, but has never fallen.
Physical exam: The patient looks well for her age. Blood
pressure is 138/75, pulse is 83 but irregularly irregular.
Cardiac exam is normal except for the irregular rhythm.
Neurological exam is normal,
including cranial nerves, visual fields and visual acuity. The
rest of the physical exam is also normal. All laboratory work
including complete blood count, electrolytes, urea,
creatinine and TSH are normal. ECG confirms atrial fibrillation
at 80 beats per minute, but is otherwise unremarkable.
Echocardiogram (performed the next day) also shows atrial
fibrillation, but is otherwise unremarkable (normal chamber
sizes, normal systolic function, and no valvular abnormalities).
3 High Stroke risk, high risk of falls
History: The patient is a 72 year old woman who lives with
her husband in her own home. She is cognitively intact, as
is her husband. Past history includes hypertension, and a
previous ischemic stroke 3 years ago, which left her with a
mild facial droop but no other neurologic deficits. She also
has Parkinson’s Disease which is well controlled but has
resulted in her falling 3 times in the last year. She walks
with a walker. Her current medications include
hydrochlorothiazide 25 mg daily, atenolol 50 mg daily,
Sinemet 100/25 mg tablets three times a day. She
recalled taking aspirin in the past, but stopped on her own
years ago.
Physical Exam: The patient has a mildly shuffling gait, but
appears well for her age. Blood pressure is 139/73, pulse is
85 but irregularly irregular. Cardiac exam is normal except
for the irregular rhythm. Neurological examination reveals
mild left-sided lower facial weakness consistent with her
past stroke and cogwheel rigidity of the extremities in
keeping with her Parkinson’s. The rest of the physical exam
is normal. All laboratory work including complete blood
count, electrolytes, urea, creatinine and TSH are normal.
Table 1 Details of the case vignettes (Continued)
ECG confirms atrial fibrillation at 86 beats per minute, but
is otherwise unremarkable. Echocardiogram (performed the
next day) also shows atrial fibrillation, but is otherwise
unremarkable (normal chamber sizes, normal systolic
function, and no valvular abnormalities).
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strokes (31.4%). Internal medicine specialists were the
most likely to report having seen both kinds of adverse
events (Bleed 72.7%; Stroke 41.9%), and family physi-






Province ON 162 (48.4) 360 (51.6)
Other 173 (51.6) 337 (48.4)
Physician Group Family Doctors 154 (46) 309 (44.3)
Geriatricians 52 (15.5) 84 (12.1)
Internal Medicine 129 (38.5) 304 (43.6)
Gender Male 221 (65.9) 456 (65.4)
Female 112 (33.4) 233 (33.4)
Missing 2 (0.6) 8 (1.1)



























Table 3 Estimated mean percentages of new patients treated with defined anti-thrombotic therapies
When you see new patients with atrial fibrillation, for what percentage do you administer the following
anti-thrombotic therapies?
All (n = 331) Geriatricians (n = 51) Family doctors (n = 151) Internal Medicine Specialists (n = 129) P-value§
Warfarin 72.6% 76.4% 71.9% 71.9% 0.28
no antithrombotic therapy 5.4% 4.9% 5.3% 5.8% 0.21
Aspirin 20.7% 19.8% 20.4% 21.5% 0.24
Plavix (Clopidogrel) 4.2% 3.8% 5.2% 3.2% 0.11
Other 2.9% 1.6% 2.7% 3.6% 0.46
§Kruskal-Wallis; P < 0.05.
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Warfarin prescription decisions were made by respon-
dents for three hypothetical patients 1) low stroke risk,
low falls risk; 2) high stroke risk, low falls risk; 3) high
stroke risk, high falls risk; data are shown in Figure 1.
The third vignette described a patient with a similar high
stroke risk as in vignette 2, but with the addition of a
risk of falls (3 times in the last year). Such occasional
falls are not a contraindication of warfarin prescription.
Warfarin use was lowest for the first vignette, although
physician groups varied significantly (G: 15.9%; FD: 37.2%;
IMS: 9.2%). For a patient with a high stroke risk and low
falls risk, warfarin use was universally high, and did not
differ between groups (G: 97.7%; FD: 91.2%; IMS: 95%).
Physician groups differed dramatically on whether the
addition of a falls risk would change their decision to
prescribe warfarin. Almost all (93.2%) of geriatricians re-
ported that they would prescribe warfarin for such a pa-
tient; this did not differ significantly from the proportion
that would give warfarin to a similar patient without the
falls risk (97.7%). However, only 59.2% of IMSs and
37.8% of FDs would prescribe warfarin, compared to
95% and 91.2% respectively for patients without the risk
of falls; this difference between physician groups wasTable 4 Physician reasons for not prescribing Warfarin (n = 33
When you do NOT initiate War
fibrillation, what reasons accou
All Geriatricians
(n = 51)
Patient judged low risk 55.5% 25.5%a
Bleeding risk 67.3% 52.9%a
Fall risk 68.2% 47.1%a
Advanced age 25.5% 7.8%a
Expected poor patient compliance 59.7% 74.5%a
Monitoring/management logistical issues 26.4% 52.9%a
Other 14.5% 19.6%a
§Kruskal-Wallis; P < 0.05. Subscripts denote a subset of physician group categories w
columns both containing the subscript ‘a’ are similar, but can be differentiated from
from columns containing ‘a’ or ‘b’.significant (Fisher’s exact test p < 0.01, Pearson χ2(6) =
45.446, p < 0.01). Stated another way, while only 4.5% of
geriatricians reported a different warfarin prescription
decision between vignettes 2 and 3, the number was
36.7% for Internal Medicine Specialists and 54.1% for
Family Physicians.
Finally, we combined the data from the three physician
groups to examine whether prior experience with a pa-
tient having had a stroke or bleed would be related
to reduced likelihood of warfarin given an occasional
risk of falls i.e. change in practice between vignettes two
and three. Experience with having seen a serious bleed
was not associated with that likelihood (χ2 (3) =3.039,
p = 0.386, Fisher’s exact test p = 0.319, n = 308). However,
experience with having seen a stroke in a patient not
prescribed warfarin was a significant influence; those
who had a patient experience a stroke while not receiving
warfarin were more likely to persist with, or introduce, the
prescription of warfarin in the presence of risk of falls (χ2
(3) = 10.7, p = 0.013, Fisher’s exact test p = 0.013, n = 301).
Discussion
Consistent with previous research, [11,28,35-40] the
present study observed variation in reported prescribing0)
farin (Coumadin) treatment for patients who have chronic atrial













hose column proportions are similar at the P = 0.05 level. For example,
columns containing b. Columns containing ‘a,b’ cannot be differentiated
Table 5 Physician experience of adverse events of serious bleed or stroke in patients
Experience
All Geriatricians Family doctors Internal Medicine
Specialists
P-value§
Ever had a patient suffer a serious bleed (% Yes) (n = 330) 60.3% 60.8%a,b 49.7%a 72.7%b <0.01
Have you ever had a patient suffer a serious stroke (% Yes) (n = 322) 31.4% 34.7%a,b 21.5%a 41.9%b <0.01
§χ2. Each subscript letter denotes a subset of physician group categories whose column proportions are similar at the P = 0.05 level. For example, columns both
containing the subscript ‘a’ are similar, but can be differentiated from columns containing b. Columns containing ‘a,b’ cannot be differentiated from columns
containing ‘a’ or ‘b’.
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variables such as perceived bleeding risk, fall risk, and
expected poor patient adherence as commonly cited fac-
tors that would decrease physicians’ likelihood of pre-
scribing warfarin. While previous studies have indicated
the role of factors such as perceived risk of falls as a bar-
rier to warfarin prescription, [2,21-23] we further this re-
search by analyzing the impact on prescribing decisions
across different physician populations.
Our results demonstrated a high reported used of war-
farin, with all physician groups stating that they pre-
scribe warfarin to 70-75% of their patients with atrial
fibrillation. This suggests that there is no one group of
physicians that is wildly different in their planned use of
the drug, either because of a lack of knowledge about
outcomes, or relevant practice differences. These rates
must, however, be cautiously interpreted given the self-
reported nature and are above the typical estimates of
current warfarin use, which have been reported to be as
low as 19%, but as high as 78% [11,28,32]. However, a
strength of the present study is the comparisons made
across different physician specialties and the reported
differences in reasons for not prescribing warfarin. Spe-












Low stroke risk, low falls
risk
High stroke risk, low falls
risk
H
Figure 1 Stated rates of treatment with conventional warfarin for eac
would prescribe conventional warfarin (INR 2.0-3.0) for each of the scenarioSeveral potential limitations of this study warrant consid-
eration. Our response rate was only 32.5%, although this is
similar to previous surveys with physicians regarding treat-
ment practices [37,38,41]. We attribute this in part to the
length of the survey, which was six pages in length and re-
quired some effort to complete. While there were no clear
differences on available variables between responders and
non-responders, and response rate was similar across phys-
ician groups, our limited knowledge about non-responders
leaves open the possibility of a response bias. A second
limitation is that the data were collected in 2007, and since
then a number of new alternatives to warfarin have be-
come available. However, a number of questions remain
over the use of new therapies due to (1) the significantly in-
creased costs over warfarin and (2) the concern regarding
the treatment of side effects – such as bleeding. Until these
issues have been addressed warfarin is likely to remain an
important treatment for atrial fibrillation.
Our results indicate that physician groups differ in terms
of the barriers reported to affect warfarin-prescribing deci-
sions. While previous research identified geriatricians as
being more likely to indicate warfarin prescription than
other physicians types, [42] it only compared responses to
two scenarios that varied in several aspects. Our results






h scenario (n = 312). Percentage of physicians reporting that they
s presented in Table 1.
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and advanced age as less influential on prescribing deci-
sions than the other physician groups. Similarly, family
doctors were less likely than geriatricians to indicate they
would be affected by logistical issues such as poor patient
adherence and monitoring issues. One suggestion may be
that family doctors may be more likely to refer these
patients to other specialties and so may be less likely to
experience adherence issues. Whether these group dif-
ferences can be best explained by experience, training, or
as a reflection of the capabilities of their respective patient
populations requires further investigation. The subsequent
development of tools such as HAS-BLED, [43] HEM-
ORR2HAGES, [44] and ATRIA [45] for the assessment
of bleeding risk – and which explicitly incorporate
advanced age – may assist standardizing risk assess-
ments for bleeding as part of the clinical assessments as
to the net clinical benefit of oral anti-coagulants, [46]
although there remains an ongoing need for assessment of
prospective clinical utility.
Prior experience of patients suffering adverse events also
appeared to affect prescribing practice. Aggregated phys-
ician data indicated a positive association between expe-
rience of a patient suffering a stroke when not prescribed
warfarin and an indication that they would continue or in-
stigate prescribing of warfarin in the presence of falls risk.
We did not, however, find an association between experi-
ence of adverse bleeding and warfarin prescription in the
presence of falls risk. This finding is consistent with several
other survey-based studies [22,41]. Using a cross-sectional
survey of physicians within the American Medical Asso-
ciation, Gross et al., [41] reported more physicians to ex-
perience regret over acts of omission (not prescribing
warfarin and then stroke) than commission (prescribing
warfarin then bleed) and an associated increase in stated
warfarin prescription when presented with a range of case
vignettes [41]. This accords with Australian data from
family physicians [22] in which one fifth felt responsible for
acts of commission leading to hemorrhage, whilst just
under a third reported they would feel responsible for an
act of omission that lead to an ischemic stroke. However,
in a study of actual prescribing and past patient bleeding/
stroke, an association between physician experience of ser-
ious bleeding and reduced warfarin prescription was found
[25]. This may point to a disagreement between self-
reported and actual behavior which indicates an important
area requiring further study.
Overall, and consistent with previous results, [22] we
saw a general drop in the proposed use of conventional
warfarin when the risk of recurrent falls was introduced
within the vignettes. However, an intriguing result was the
clear differences in how the different physician groups in-
corporate falls risk into their decisions. Inclusion of falls
risk into an otherwise comparable, high stroke risk patientresulted in avoidance of warfarin in 37% of Internal Medi-
cine Specialists, 54% of Family Physicians, and only 5% of
Geriatricians. While older patients have not been included
in clinical trials, and so one might expect geriatricians to
be more conservative in their use of warfarin, geriatricians
may have greater clinical experience with how warfarin
might affect older patients through increased exposure
to atrial fibrillation. They may, therefore, be basing
their decisions on this clinical experience as opposed to
trial data. Whether such differences in the stated use of
warfarin in the presence of falls can be attributable to
reasonable differences in practice, or whether it points
to a misunderstanding of the risk associated with falls
in one or more physician group is an important area
for further research, particularly given the lack of trial
data relating to older patients, those at increased risk of
falls, and at higher risk of stroke.
Conclusion
Our study provides a number of insights into self-
reported physician prescribing practice and the barriers to
prescribing warfarin. Our results replicate previous studies
and identify a number of potential barriers to warfarin
prescription, but have identified differing impact across
physician populations. In particular, we note the variation
regarding adverse events on stated prescribing practice;
prior experience of a patient suffering a stroke when not
prescribed warfarin was positively associated with an
intention to prescribe warfarin, even in the presence of
falls risk. The indication that physicians of differing
specialty don’t report significantly different rates of prac-
tice may indicate that general educational interventions
will be ineffective. Rather, specific patient- or practice-
level feedback may be appropriate. Harnessing the poten-
tial of electronic medical records and techniques such as
audit and feedback, [47,48] may provide ‘personalized’
feedback on clinical practice that will be both more salient
and informative with respect to monitoring prescribing
practice for warfarin [49]. Our results provide insight into
where variation in physician decision making occurs and
may point to relevant elements to be included in such
feedback. Despite this suggestion, there remains a need
for further research to explore how physicians weight spe-
cific indicators under different scenarios and to investigate
how new agents will modify decisions given the notable
impact of monitoring on physician practice.
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